CF PharmTech (2652) Announces Plan for H Share Full Circulation

Bulletin Express11-25

CF PharmTech, Inc. (the “Company”) has approved a proposed plan to convert 107,408,422 domestic unlisted shares, representing approximately 26.1% of its total issued share capital as of the announcement date, into H shares for listing on the Main Board of The Stock Exchange of Hong Kong Limited. This process, known as H Share Full Circulation, requires filing with the China Securities Regulatory Commission (CSRC).

The announcement states that the domestic unlisted shares will be converted into H shares upon obtaining all necessary approvals and meeting relevant regulatory requirements. The Company will seek approval from the Stock Exchange for the listing of these newly converted shares.

According to the announcement, the application documents have not yet been submitted to the CSRC. Shareholders and potential investors are urged to exercise caution when dealing in the Company’s securities, as the proposed conversion is subject to additional regulatory procedures and approvals.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1118840248?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-25 18:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118840248","market":"hk","top_or_hot":-1,"title":"CF PharmTech (2652) Announces Plan for H Share Full Circulation","media":"Bulletin Express","content":"<p>CF PharmTech, Inc. (the “Company”) has approved a proposed plan to convert 107,408,422 domestic unlisted shares, representing approximately 26.1% of its total issued share capital as of the announcement date, into H shares for listing on the Main Board of The Stock Exchange of Hong Kong Limited. This process, known as H Share Full Circulation, requires filing with the China Securities Regulatory Commission (CSRC).</p>\n<p>The announcement states that the domestic unlisted shares will be converted into H shares upon obtaining all necessary approvals and meeting relevant regulatory requirements. The Company will seek approval from the Stock Exchange for the listing of these newly converted shares.</p>\n<p>According to the announcement, the application documents have not yet been submitted to the CSRC. Shareholders and potential investors are urged to exercise caution when dealing in the Company’s securities, as the proposed conversion is subject to additional regulatory procedures and approvals.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CF PharmTech (2652) Announces Plan for H Share Full Circulation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCF PharmTech (2652) Announces Plan for H Share Full Circulation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-25 18:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CF PharmTech, Inc. (the “Company”) has approved a proposed plan to convert 107,408,422 domestic unlisted shares, representing approximately 26.1% of its total issued share capital as of the announcement date, into H shares for listing on the Main Board of The Stock Exchange of Hong Kong Limited. This process, known as H Share Full Circulation, requires filing with the China Securities Regulatory Commission (CSRC).</p>\n<p>The announcement states that the domestic unlisted shares will be converted into H shares upon obtaining all necessary approvals and meeting relevant regulatory requirements. The Company will seek approval from the Stock Exchange for the listing of these newly converted shares.</p>\n<p>According to the announcement, the application documents have not yet been submitted to the CSRC. Shareholders and potential investors are urged to exercise caution when dealing in the Company’s securities, as the proposed conversion is subject to additional regulatory procedures and approvals.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"长风药业","start_time":0,"source_url":"","article_id":"1118840248","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118840248","pubTimestamp":1764067383,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CF PharmTech, Inc. (the “Company”) has approved a proposed plan to convert 107,408,422 domestic unlisted shares, representing approximately 26.1% of its total issued share capital as of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02652":"长风药业"},"translate_title":"CF PharmTech(2652)公布H股全流通计划","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1},"content_text":"CF PharmTech, Inc. (the “Company”) has approved a proposed plan to convert 107,408,422 domestic unlisted shares, representing approximately 26.1% of its total issued share capital as of the announcement date, into H shares for listing on the Main Board of The Stock Exchange of Hong Kong Limited. This process, known as H Share Full Circulation, requires filing with the China Securities Regulatory Commission (CSRC).\nThe announcement states that the domestic unlisted shares will be converted into H shares upon obtaining all necessary approvals and meeting relevant regulatory requirements. The Company will seek approval from the Stock Exchange for the listing of these newly converted shares.\nAccording to the announcement, the application documents have not yet been submitted to the CSRC. Shareholders and potential investors are urged to exercise caution when dealing in the Company’s securities, as the proposed conversion is subject to additional regulatory procedures and approvals.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1118840248","isCrawlerRequest":true}